Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 438 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: coagulation study Clear all
Terminated Phase 2 Interventional Results available

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

NCT00623974
View directory record Official record
Conditions
Hypocalcemia
Interventions
Teriparatide (Forteo), Calcium, Calcitriol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 22, 2026, 4:13 PM EDT
Completed No phase listed Observational

Thromboelastography-Guided Fluid Management in Spinal Surgery

NCT03999086
View directory record Official record
Conditions
Spinal Fusion
Interventions
Intervention, Control Group
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 22, 2026, 4:13 PM EDT
Not yet recruiting Not applicable Interventional

Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage

NCT07577739
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Cerebral Vasospasm, Autonomic Nervous System Diseases
Interventions
Right-Sided Cervical Sympathetic Block at C6, Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)
Procedure · Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
D. Walter Wray
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

NCT04545554
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Romosozumab, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

NCT00321932
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
Interventions
calcium, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma

NCT04850222
View directory record Official record
Conditions
Musculoskeletal Injury
Interventions
Fluoxetine, Calcium
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Not applicable Interventional

Study of Choroid Plexus Cauterization in Patients With Hydrocephalus

NCT02900222
View directory record Official record
Conditions
Hydrocephalus
Interventions
endoscopic choroid plexus coagulation
Procedure
Lead sponsor
Ronald Benveniste
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

NCT05053139
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
NNC0365-3769 (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 22, 2026, 4:13 PM EDT
Recruiting Phase 3 Interventional

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 74 Years · Male only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Simulines Non-Inferiority Pivotal Study

NCT02736825
View directory record Official record
Conditions
Skin Laxity
Interventions
Ulthera System with standard transducer, Ulthera System with prototype 2 simulines transducer
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
30 Years to 70 Years
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Roseville, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 22, 2026, 4:13 PM EDT
Completed No phase listed Observational

Use of ROTEM® in Pediatric Cardiac Surgical Patients

NCT01212289
View directory record Official record
Conditions
Congenital Heart Defect
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 6 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 22, 2026, 4:13 PM EDT
Terminated Phase 3 Interventional Results available

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

NCT01086852
View directory record Official record
Conditions
Factor X Deficiency
Interventions
FACTOR X
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

NCT04684940
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
Interventions
Valoctocogene roxaparvovec
Biological
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 4:13 PM EDT
Completed No phase listed Observational

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

NCT06352125
View directory record Official record
Conditions
Surgery
Interventions
TEG 6s Citrated K, KH, RTH, FFH Cartridge, Clauss Fibrinogen
Diagnostic Test
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

NCT01496274
View directory record Official record
Conditions
Hemophilia B
Interventions
rIX-FP
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 22, 2026, 4:13 PM EDT
Completed No phase listed Observational

CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study

NCT00522002
View directory record Official record
Conditions
Connective Tissue Diseases, Blood Coagulation Disorders, Leg Ulcers, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Scleroderma, Mixed Connective Tissue Disease
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 22, 2026, 4:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older

NCT03074266
View directory record Official record
Conditions
Blood Coagulation Test
Interventions
GEM Hemochron 100 ACT
Diagnostic Test
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 22, 2026, 4:13 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Cyclic Versus Daily Teriparatide on Bone Mass

NCT00668941
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy

NCT03526263
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity; Endocrine, Bariatric Surgery Candidate
Interventions
Gastric mucosal devitalization
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
28 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564
View directory record Official record
Conditions
Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases, Rheumatic Diseases
Interventions
Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
135
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 22, 2026, 4:13 PM EDT
Not listed Not applicable Interventional

Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Validation Study

NCT05870943
View directory record Official record
Conditions
Obesity
Interventions
Hybrid Argon Plasma Coagulation, Endoscopic Sleeve Gastroplasty
Procedure
Lead sponsor
True You Weight Loss
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 22, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins

NCT00082355
View directory record Official record
Conditions
Acute Deep Venous Thrombosis of the Lower Extremity
Interventions
Alteplase (Activase, Genentech)
Drug
Lead sponsor
Richard Chang, M.D.
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 22, 2026, 4:13 PM EDT
Active, not recruiting Not applicable Interventional

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

NCT02766543
View directory record Official record
Conditions
Prostate Cancer
Interventions
MRI-guided Transurethral Ultrasound Ablation
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 22, 2026, 4:13 PM EDT